At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2 enrolled
Drug / intervention
Gemcitabine +1 moredrug
Likely dose
Gemcitabine 300 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Proton radiation and Gemcitabine for Pancreatic Cancer. Completed, enrolled 2 participants across 2 sites.
Detailed Summary
The purpose of this study is to find out what effects, good and/or bad, proton radiation combined with chemotherapy has on resected pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedMar 2012
Primary CompletionAug 2017
TodayJul 2026
First PostedMar 13, 2012
Enrollment StartOct 1, 2011
Primary CompletionAug 31, 2017
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 14.3 years ago
Interventions
Proton radiationradiation
Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
Gemcitabinedrug
Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.